Vera Therapeutics Accelerates Path to Full FDA Approval for Atacicept in IgA Nephropathy
Event summary
- Vera Therapeutics aligns with FDA on earlier eGFR analysis for atacicept, now expected in Q3 2026.
- Pending positive results, Vera plans to submit a supplemental BLA in Q4 2026 for potential full approval in 2027.
- ORIGIN Phase 3 trial met primary endpoint with significant proteinuria reduction at week 36.
- Atacicept has Breakthrough Therapy Designation for IgA Nephropathy, targeting BAFF and APRIL cytokines.
The big picture
Vera Therapeutics' strategic shift to an earlier FDA analysis reflects growing confidence in atacicept's efficacy data, potentially positioning it as the first approved therapy targeting BAFF and APRIL in IgA Nephropathy. The move aligns with broader industry trends toward accelerated approval pathways for treatments addressing high unmet medical needs. Success here could validate Vera's pipeline strategy and attract further investment in its autoimmune disease portfolio.
What we're watching
- Regulatory Timing
- Whether the accelerated eGFR analysis timeline will maintain data integrity and support full approval.
- Market Positioning
- How atacicept's best-in-class potential will compete in the IgA Nephropathy treatment landscape.
- Clinical Expansion
- The pace at which Vera can expand atacicept's use into other autoimmune diseases beyond IgAN.
Related topics